GeoVax Relocates Headquarters and Labs to Atlanta Area to Fuel Growth and Pipeline Advancement
GeoVax Labs is relocating its corporate headquarters and laboratory operations to new Atlanta-area facilities, positioning the clinical-stage biotechnology company for accelerated growth, late-stage development, and future commercialization of its cancer and infectious disease therapies.
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and multi-antigen vaccines against cancers and infectious diseases, announced relocations of its corporate headquarters and laboratory operations to new facilities in the Atlanta metropolitan area. The moves, scheduled for fourth quarter of 2025, will support GeoVax's continued growth, expanding pipeline, and preparation for product commercialization.
GeoVax's laboratory group is relocating to Science Square / Portal Innovations, located in midtown Atlanta. This state-of-the-art facility will provide the Company's R&D team with expanded access to modern laboratories and collaborative research environments designed to accelerate innovation and development activities. The Company's new corporate headquarters will be located at 1955 Lake Park Drive in Smyrna, Georgia, establishing a new hub for corporate operations and leadership activities.
These relocations strengthen GeoVax's ties to Georgia's bio-ecosystem and position the company for late-stage development and market readiness. David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that these moves reflect a significant milestone in the company's evolution. By placing members of the R&D team in one of the most dynamic bio-research ecosystems in the Southeast, and by expanding the administrative base, GeoVax is positioning itself for an accelerated next stage of growth.
The facilities will support GeoVax's broad and advancing pipeline, which includes the promising GEO-MVA program and multiple clinical trials in cancer therapy and infectious disease vaccines. Eddie Lai, Director of Business Development at Atlanta Portal Innovations, expressed excitement about GeoVax joining the Portal Innovations ecosystem, noting that the company brings a strong legacy of innovation rooted in the Southeast to an ecosystem that includes 100+ innovative companies utilizing Portal sites across the country.
The relocations underscore GeoVax's trajectory as a company focused on long-term growth, scientific advancement, and future commercialization opportunities. As the Company builds momentum with a deepening pipeline and strategic partnerships, its enhanced infrastructure will provide a strong foundation to meet global healthcare needs. For more information about the current status of clinical trials and other updates, visit https://www.geovax.com.